Form 4 for ACRV Acrivon Therapeutics, Inc.
Accepted 2026-08-20 16:08:39 ET · period of report 2026-08-18 · accession 0000905148-26-003838 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-20 16:08 | 2026-08-18 | ACRV | Gamelin Erick | Chief Development Off | S - Sale | $2.01 | -400 | 52.6K | -0.8% | -$804.00 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-18 | S | D | 400 | $2.01 | 52,592 | D | — | — | (F1) Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. |